Pancreatic Cancer Research

ResearcherUniversity of PalermoActive in the last 2 years

Daniela Carbone

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5969-7023; OpenAlex author ID A5047535840. Sources: OpenAlex.

Their work

Papers
20 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
29
Papers, trials and grants by year

2019: 1 paper · 2020: 3 papers · 2021: 5 papers · 2022: none · 2023: 3 papers · 2024: 4 papers · 2025: 3 papers · 2026: 1 paper

Papers 20

  1. 3-amino-1,2,4-triazine scaffolds as next-generation PDK inhibitors: Design, mechanistic insights, and efficacy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejmech.2026.119202↗
  2. Novel Pyrazolo [1,5-a]-1,3,5-Triazine Derivatives as CDK7 Inhibitors: Synthesis and Biological Insights in Pancreatic Ductal Adenocarcinoma Models. Co-author DOI 10.1002/cmdc.202500448↗
  3. Corrigendum to "Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promising anticancer activity in pancreatic c… Co-author DOI 10.1016/j.bioorg.2024.107995↗
  4. New Marine-Inspired Oxadiazole Derivatives for Use Against Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/md23080327↗
  5. Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promising anticancer activity in pancreatic cancer models. Co-author DOI 10.1016/j.bioorg.2024.107959↗
  6. Exploring the therapeutic potential of a novel series of imidazothiadiazoles targeting focal adhesion kinase (FAK) for pancreatic cancer treatment: synthesis, … First author DOI 10.1080/1061186x.2024.2385557↗
  7. Exploring the therapeutic potential of focal adhesion kinase inhibition in overcoming chemoresistance in pancreatic ductal adenocarcinoma. Last author DOI 10.4155/fmc-2023-0234↗
  8. Exploring Splicing Modulation as an Innovative Approach to Combat Pancreatic Cancer: SF3B1 Emerges as a Prognostic Indicator and Therapeutic Target. Co-author DOI 10.7150/ijbs.92671↗
  9. Discovery of the 3-Amino-1,2,4-triazine-Based Library as Selective PDK1 Inhibitors with Therapeutic Potential in Highly Aggressive Pancreatic Ductal Adenocarci… Co-author DOI 10.3390/ijms24043679↗
  10. Structural Manipulations of Marine Natural Products Inspire a New Library of 3-Amino-1,2,4-Triazine PDK Inhibitors Endowed with Antitumor Activity in Pancreati… Co-author DOI 10.3390/md21050288↗
  11. 1,3,4-Oxadiazole and 1,3,4-Thiadiazole Nortopsentin Derivatives against Pancreatic Ductal Adenocarcinoma: Synthesis, Cytotoxic Activity, and Inhibition of CDK1. Co-author DOI 10.3390/md21070412↗
  12. 1,2,4-Oxadiazole Topsentin Analogs with Antiproliferative Activity against Pancreatic Cancer Cells, Targeting GSK3β Kinase. Co-author DOI 10.1002/cmdc.202000752↗
  13. GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer. Co-author DOI 10.1016/j.drup.2021.100779↗
  14. SF3B1 modulators affect key genes in metastasis and drug influx: a new approach to fight pancreatic cancer chemoresistance. Co-author DOI 10.20517/cdr.2021.61↗
  15. Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC). Co-author DOI 10.3390/cancers13174389↗
  16. A New Oxadiazole-Based Topsentin Derivative Modulates Cyclin-Dependent Kinase 1 Expression and Exerts Cytotoxic Effects on Pancreatic Cancer Cells. Last author DOI 10.3390/molecules27010019↗
  17. Imidazo[2,1-b] [1,3,4]thiadiazoles with antiproliferative activity against primary and gemcitabine-resistant pancreatic cancer cells. Co-author DOI 10.1016/j.ejmech.2020.112088↗
  18. "Open Sesame?": Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Up… Co-author DOI 10.3390/cancers12113206↗
  19. 3-(6-Phenylimidazo [2,1-b][1,3,4]thiadiazol-2-yl)-1H-Indole Derivatives as New Anticancer Agents in the Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/molecules25020329↗
  20. Biological Evaluation of the Antiproliferative and Anti-migratory Activity of a Series of 3-(6-Phenylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)-1H-indole Derivative… Co-author DOI 10.21873/anticanres.13509↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Patrizia Diana · 19 shared papers, 2019–2026 · strength 3.33
  2. Barbara Parrino · 17 shared papers, 2019–2026 · strength 2.98
  3. Camilla Pecoraro · 15 shared papers, 2021–2026 · strength 2.86
  4. Elisa Giovannetti · 17 shared papers, 2019–2025 · strength 2.83
  5. Stella Cascioferro · 15 shared papers, 2019–2025 · strength 2.43
  6. Godefridus J. Peters · 10 shared papers, 2019–2025 · strength 1.35
  7. Geng Xu · 5 shared papers, 2023–2025 · strength 1.09
  8. Fabio Scianò · 4 shared papers, 2024–2025 · strength 0.90
  9. Juan Deng · 2 shared papers, 2024–2025 · strength 0.47
  10. Btissame El Hassouni · 3 shared papers, 2019–2024 · strength 0.37
  11. Giovanna Li Petri · 3 shared papers, 2019–2020 · strength 0.29
  12. Cecilia Bergonzini · 2 shared papers, 2020–2024 · strength 0.29
  13. Amir Avan · 2 shared papers, 2021 · strength 0.27
  14. Mahrou Vahabi · 1 shared paper, 2025 · strength 0.27
  15. Giulia Lencioni · 1 shared paper, 2025 · strength 0.27
  16. Ornella Randazzo · 2 shared papers, 2020–2021 · strength 0.23
  17. Niccola Funel · 2 shared papers, 2020 · strength 0.20
  18. Annalisa Comandatore · 1 shared paper, 2024 · strength 0.18
  19. Amir Avan · 1 shared paper, 2024 · strength 0.18
  20. Giulia Mantini · 1 shared paper, 2024 · strength 0.18
  21. I Gede Putu Supadmanaba · 1 shared paper, 2024 · strength 0.18
  22. Rocco Sciarrillo · 1 shared paper, 2024 · strength 0.18
  23. Luca Morelli · 1 shared paper, 2024 · strength 0.18
  24. Rosa Wijnen · 1 shared paper, 2021 · strength 0.14
  25. Amir Avan · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.